Cadila jumps as USFDA issues no observation on Moraiya facility
Drug maker Cadila Healthcare has announced that its manufacturing facility in Moraiya, Gujarat was inspected by the USFDA with no form 483 issued against the company.
Cadila Healthcare said that the USFDA inspected our Moraiya facility from February 6, 2017 to February 15, 2017. At the end of the inspection, no observation (483) is issued.’
A Form 483 is issued by the FDA when its investigators observe any conditions that in their judgment may constitute violations of the US Food Drug and Cosmetic Act.
Sun Pharma surges on Tentative USFDA nod for Tadalafil Tablets
Sun Pharma gets Tentative USFDA nod for Tadalafil Tablets (used to treat erectile dysfunction & arterial hypertension) – positive read through for the stock
TCS up as board to consider buyback of shares
Tata Consultancy Services has announced that the Board of Directors will consider a proposal for buyback of equity shares of the Company at its meeting to be held on February 20, 2017.
Reacting to this news shares of Tata Consultancy Services (TCS) rose by 2.55% to Rs2477.5.
Cipla gets USFDA nod for Oxaliplatin Injectable
Cipla gets USFDA nod for Oxaliplatin Injectable (used to treat colorectal cancer) – positive read through for the stock.
M&M to hike capacity of MHCV to cater to increased demand
Mahindra and Mahindra is hiking production of its trucks with the introduction of a second shift at its Chakan plant to meet increased orders for the Blazo vehicles.
M&M also introduced a service support initiative for its commercial vehicles on the Delhi-Mumbai service corridor. Currently, M&M sells about 500 units on monthly basis.
Capitalstars Financial Research Private Limited is a research house and an investment advisory carrying out operations in the Indian Equities and Commodity market.We also provide 2 days free trial to our client.Join our services and trade with us.
GET MORE DETAILS HERE:-